- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism based drug discovery and clinical implications.
Andere Kunden interessierten sich auch für
- Sandy WeinbergGuidebook for Drug Regulatory Submissions147,99 €
- Blood-Brain Barrier in Drug Discovery170,99 €
- John L. LaMattinaDrug Truths30,99 €
- Jianling WangPredictive Admet177,99 €
- Polypharmacology in Drug Discovery157,99 €
- Jie-Jack LiDrug Discovery146,99 €
- Applications of Ion Chromatography for Pharmaceutical and Biological Products157,99 €
-
-
-
This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism based drug discovery and clinical implications.
Produktdetails
- Produktdetails
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 508
- Erscheinungstermin: 1. März 2011
- Englisch
- Abmessung: 240mm x 161mm x 32mm
- Gewicht: 911g
- ISBN-13: 9780470343425
- ISBN-10: 0470343427
- Artikelnr.: 30976957
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 508
- Erscheinungstermin: 1. März 2011
- Englisch
- Abmessung: 240mm x 161mm x 32mm
- Gewicht: 911g
- ISBN-13: 9780470343425
- ISBN-10: 0470343427
- Artikelnr.: 30976957
MINGHAN "MING" WANG, PHD is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.
Introduction (Minghan Wang). Contributors. Part I. The physiology of
metabolic tissues under normal and disease states. Chapter 1: Gut as an
endocrine organ: the role of nutrient-sensing in energy metabolism (Minghan
Wang). Chapter 2: Central glucose sensing and control of food intake and
energy homeostasis (Lourdes Mounien and Bernard Thorens). Chapter 3:
Abnormalities in insulin secretion in type 2 diabetes mellitus (Taly Meas
and Pierre-Jean Guillausseau). Chapter 4: Adipokine production by adipose
tissue: A novel target for treating metabolic syndrome and its sequelae
(Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter
Zahradka). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:
Insulin resistance and impaired glucose production and lipid synthesis
(Ruojing Yang). Chapter 6: Energy metabolism in skeletal muscle and its
link to insulin resistance (Minghan Wang). Part II. Metabolic diseases and
current therapies. Chapter 7: Mechanisms and complications of metabolic
syndrome (Minghan Wang). Chapter 8: Emerging therapeutic approaches for
dyslipidemia associated with high LDL and low HDL (Margrit Schwarz and Jae
B. Kim). Chapter 9: Mechanism of action of niacin: implications for
atherosclerosis and drug discovery (Devan Marar, Shobha H. Ganji, Vaijinath
S. Kamanna, and Moti L. Kashyap). Chapter 10: Current anti-diabetic
therapies and mechanisms (Minghan Wang). Part III. Drug targets for
anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms,
physiology, and clinical studies (Remy Burcelin, Cendrine Cabou1,
Christophe Magnan, and Pierre Gourdy). Chapter 12: Dipeptidyl peptidase IV
inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J., Pederson,
RA, Heiser, U, and Demuth, H-U). Chapter 13: Sodium glucose co-transporter
2 inhibitors (Margaret Ryan and Serge A. Jabbour). Chapter 14: Fibroblast
growth factor 21 as a novel metabolic regulator (Radmila Micanovic, James
D. Dunbar, and Alexei Kharitonenkov). Chapter 15: Sirtuins as potential
drug targets for metabolic diseases (Qiang Tong). Chapter 16:
11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2
diabetes (Clarence Hale and David J. St. Jean, Jr.). Chapter 17: Monoclonal
antibodies for the treatment of type 2 diabetes: A case study with glucagon
receptor blockade (Hai Yan, Wei Gu, and Murielle Veniant-Ellison). Part IV.
Lessons learned and future outlook. Chapter 18: Drug development for
metabolic diseases: past, present and future (Minghan Wang). Index.
metabolic tissues under normal and disease states. Chapter 1: Gut as an
endocrine organ: the role of nutrient-sensing in energy metabolism (Minghan
Wang). Chapter 2: Central glucose sensing and control of food intake and
energy homeostasis (Lourdes Mounien and Bernard Thorens). Chapter 3:
Abnormalities in insulin secretion in type 2 diabetes mellitus (Taly Meas
and Pierre-Jean Guillausseau). Chapter 4: Adipokine production by adipose
tissue: A novel target for treating metabolic syndrome and its sequelae
(Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter
Zahradka). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:
Insulin resistance and impaired glucose production and lipid synthesis
(Ruojing Yang). Chapter 6: Energy metabolism in skeletal muscle and its
link to insulin resistance (Minghan Wang). Part II. Metabolic diseases and
current therapies. Chapter 7: Mechanisms and complications of metabolic
syndrome (Minghan Wang). Chapter 8: Emerging therapeutic approaches for
dyslipidemia associated with high LDL and low HDL (Margrit Schwarz and Jae
B. Kim). Chapter 9: Mechanism of action of niacin: implications for
atherosclerosis and drug discovery (Devan Marar, Shobha H. Ganji, Vaijinath
S. Kamanna, and Moti L. Kashyap). Chapter 10: Current anti-diabetic
therapies and mechanisms (Minghan Wang). Part III. Drug targets for
anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms,
physiology, and clinical studies (Remy Burcelin, Cendrine Cabou1,
Christophe Magnan, and Pierre Gourdy). Chapter 12: Dipeptidyl peptidase IV
inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J., Pederson,
RA, Heiser, U, and Demuth, H-U). Chapter 13: Sodium glucose co-transporter
2 inhibitors (Margaret Ryan and Serge A. Jabbour). Chapter 14: Fibroblast
growth factor 21 as a novel metabolic regulator (Radmila Micanovic, James
D. Dunbar, and Alexei Kharitonenkov). Chapter 15: Sirtuins as potential
drug targets for metabolic diseases (Qiang Tong). Chapter 16:
11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2
diabetes (Clarence Hale and David J. St. Jean, Jr.). Chapter 17: Monoclonal
antibodies for the treatment of type 2 diabetes: A case study with glucagon
receptor blockade (Hai Yan, Wei Gu, and Murielle Veniant-Ellison). Part IV.
Lessons learned and future outlook. Chapter 18: Drug development for
metabolic diseases: past, present and future (Minghan Wang). Index.
Introduction (Minghan Wang). Contributors. Part I. The physiology of
metabolic tissues under normal and disease states. Chapter 1: Gut as an
endocrine organ: the role of nutrient-sensing in energy metabolism (Minghan
Wang). Chapter 2: Central glucose sensing and control of food intake and
energy homeostasis (Lourdes Mounien and Bernard Thorens). Chapter 3:
Abnormalities in insulin secretion in type 2 diabetes mellitus (Taly Meas
and Pierre-Jean Guillausseau). Chapter 4: Adipokine production by adipose
tissue: A novel target for treating metabolic syndrome and its sequelae
(Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter
Zahradka). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:
Insulin resistance and impaired glucose production and lipid synthesis
(Ruojing Yang). Chapter 6: Energy metabolism in skeletal muscle and its
link to insulin resistance (Minghan Wang). Part II. Metabolic diseases and
current therapies. Chapter 7: Mechanisms and complications of metabolic
syndrome (Minghan Wang). Chapter 8: Emerging therapeutic approaches for
dyslipidemia associated with high LDL and low HDL (Margrit Schwarz and Jae
B. Kim). Chapter 9: Mechanism of action of niacin: implications for
atherosclerosis and drug discovery (Devan Marar, Shobha H. Ganji, Vaijinath
S. Kamanna, and Moti L. Kashyap). Chapter 10: Current anti-diabetic
therapies and mechanisms (Minghan Wang). Part III. Drug targets for
anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms,
physiology, and clinical studies (Remy Burcelin, Cendrine Cabou1,
Christophe Magnan, and Pierre Gourdy). Chapter 12: Dipeptidyl peptidase IV
inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J., Pederson,
RA, Heiser, U, and Demuth, H-U). Chapter 13: Sodium glucose co-transporter
2 inhibitors (Margaret Ryan and Serge A. Jabbour). Chapter 14: Fibroblast
growth factor 21 as a novel metabolic regulator (Radmila Micanovic, James
D. Dunbar, and Alexei Kharitonenkov). Chapter 15: Sirtuins as potential
drug targets for metabolic diseases (Qiang Tong). Chapter 16:
11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2
diabetes (Clarence Hale and David J. St. Jean, Jr.). Chapter 17: Monoclonal
antibodies for the treatment of type 2 diabetes: A case study with glucagon
receptor blockade (Hai Yan, Wei Gu, and Murielle Veniant-Ellison). Part IV.
Lessons learned and future outlook. Chapter 18: Drug development for
metabolic diseases: past, present and future (Minghan Wang). Index.
metabolic tissues under normal and disease states. Chapter 1: Gut as an
endocrine organ: the role of nutrient-sensing in energy metabolism (Minghan
Wang). Chapter 2: Central glucose sensing and control of food intake and
energy homeostasis (Lourdes Mounien and Bernard Thorens). Chapter 3:
Abnormalities in insulin secretion in type 2 diabetes mellitus (Taly Meas
and Pierre-Jean Guillausseau). Chapter 4: Adipokine production by adipose
tissue: A novel target for treating metabolic syndrome and its sequelae
(Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter
Zahradka). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:
Insulin resistance and impaired glucose production and lipid synthesis
(Ruojing Yang). Chapter 6: Energy metabolism in skeletal muscle and its
link to insulin resistance (Minghan Wang). Part II. Metabolic diseases and
current therapies. Chapter 7: Mechanisms and complications of metabolic
syndrome (Minghan Wang). Chapter 8: Emerging therapeutic approaches for
dyslipidemia associated with high LDL and low HDL (Margrit Schwarz and Jae
B. Kim). Chapter 9: Mechanism of action of niacin: implications for
atherosclerosis and drug discovery (Devan Marar, Shobha H. Ganji, Vaijinath
S. Kamanna, and Moti L. Kashyap). Chapter 10: Current anti-diabetic
therapies and mechanisms (Minghan Wang). Part III. Drug targets for
anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms,
physiology, and clinical studies (Remy Burcelin, Cendrine Cabou1,
Christophe Magnan, and Pierre Gourdy). Chapter 12: Dipeptidyl peptidase IV
inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J., Pederson,
RA, Heiser, U, and Demuth, H-U). Chapter 13: Sodium glucose co-transporter
2 inhibitors (Margaret Ryan and Serge A. Jabbour). Chapter 14: Fibroblast
growth factor 21 as a novel metabolic regulator (Radmila Micanovic, James
D. Dunbar, and Alexei Kharitonenkov). Chapter 15: Sirtuins as potential
drug targets for metabolic diseases (Qiang Tong). Chapter 16:
11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2
diabetes (Clarence Hale and David J. St. Jean, Jr.). Chapter 17: Monoclonal
antibodies for the treatment of type 2 diabetes: A case study with glucagon
receptor blockade (Hai Yan, Wei Gu, and Murielle Veniant-Ellison). Part IV.
Lessons learned and future outlook. Chapter 18: Drug development for
metabolic diseases: past, present and future (Minghan Wang). Index.